Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (
CHANGE IN RATINGS
downgraded at RBC from Top Pick to Outperform, RBC Capital said. Estimates also cut, following new healthcare reform rules. $60 price target.
downgraded at Goldman from Neutral to Sell, Goldman Sachs said. Valuation call.
downgraded at Oppenheimer to Perform, Oppenheimer said. Valuation call, based on a $51 price target.
upgraded at RBC from Outperform to Top Pick, RBC Capital said. $57 price target. Company is cutting costs and has potential operating leverage in the new year.
initiated at Barclays with an Equal Weight rating and $56 price target. Pricing and competition will impede top-line growth and profitability in 2011 & 2012, Barclays said.
downgraded at RBC from Outperform to Sector Perform, RBC Capital said. Valuation call.
downgraded at Goldman from Buy to Neutral, Goldman Sachs said. Company could be hurt by lower state Medicaid reimbursement.
upgraded at Morgan Stanley to Equal-weight, Morgan Stanley said. Company continues to grow in Latin America. $20 price target.
upgraded at Baird from Neutral to Outperform, Robert Baird said. $17 price target. Industry trends are beginning to improve.
rated new Neutral at Jefferies. $30 price target. Company is a market leader in the Chinese retail market, which can grow nearly 50% annually.
upgraded at BMO from Market Perform to Outperform, BMO Capital said. $30 price target. Company is gaining market share.
rated new Hold at Jefferies. $31 price target. Company can generate double-digit organic earnings growth.
upgraded at Citigroup from Hold to Buy, Citigroup said. $5.25 price target. Potential negative regulatory headlines from NJ have passed.
initiated at Barclays with an Overweight rating and $66 price target. Multiple drug and device opportunities should provide upside to estimates and support long-term EPS growth, Barclays said.
downgraded at Goldman from Neutral to Sell, Goldman Sachs said. Company will likely be hurt by Medicare Advantage cuts.
downgraded at Citigroup from Hold to Sell, Citigroup said. Valuation call, based on a $12 price target.
initiated at Barclays with an Equal Weight rating and $20 price target. LEDS is an emerging high brightness LED supplier offering quality and cost leadership, Barclays said. 2011 and 2012 EPS estimates set at $0.70 and $0.91, respectively.
upgraded at RBC from Sector Perform to Outperform, RBC Capital said. Valuation call, as the company is a good inflation play. $85 price target.
downgraded at Stifel from Buy to Hold, Stifel Nicolaus said. Valuation call, as the company lacks near-term catalysts.
upgraded at JP Morgan from Underweight to Overweight, JP Morgan said. Company has exposure to mobile devices and networking.
downgraded at BMO from Outperform to Market Perform, BMO Capital said. Valuation call, based on a $22 price target.
( PCX) upgraded at Goldman from Sell to Neutral, Goldman Sachs said. Company has leverage to higher met coal prices.
upgraded at Deutsche from Hold to Buy, Deutsche Bank said. $22 price target. Company can generate better sales growth in the new year.
downgraded at BB&T from Buy to Hold, BB&T Capital said. Company is facing flat near-term earnings growth.
downgraded at Morgan Keegan from Outperform to Market Perform, Morgan Keegan said. $55 price target. Stock is already pricing in potential takeover speculation.
downgraded at Deutsche from Buy to Hold, Deutsche Bank said. Valuation call, as the stock gained more than 60% in 2010.
downgraded at Morgan Stanley from Overweight to Equal-weight, Morgan Stanley said. Estimates also cut, as fundamentals are deteriorating. $19 price target.
rated new Neutral at Piper Jaffray. Valuation call, based on a $40 price target.
This article was written by a staff member of TheStreet.